Douglas G Tincello1, Anthony C H Walker. 1. Department of Obstetrics and Gynaecology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, P.O. Box 65, Leicester LE27LX, UK. dgt4@le.ac.uk
Abstract
PURPOSE: To examine the site, severity, and duration, of symptoms in patients with interstitial cystitis. To examine the treatments offered. MATERIALS AND METHODS: Postal questionnaire administered to members of the Interstitial Cystitis Support Group, based in the United Kingdom. RESULTS: 736 of 1148 (64%) questionnaires were returned. 696 (94.6%) patients were women. 471 patients (64%) described daily pain when symptoms were at their worst, and 273 (37%) described daily pain at the time of survey. Most patients reported frequency, urgency and nocturia. A wide range of treatments had been offered, but drugs of proven efficacy were offered to less than a third of patients: cimetidine (36%); antihistamines (5%); pentosan polysulphate (12%); DMSO (33%); and anticonvulsants (2%). 495 patients (67%) reported "considerable impact" or more on their lifestyle and 346 (46%) reported moderate depression or worse. 364 (49%) reported at least considerable difficulties with sexual intercourse. CONCLUSIONS: This survey supports the work of others about the nature of symptoms and their impact upon quality of life. The data highlight the continuing difficulty in making a prompt diagnosis. We recommend that a European survey or registry of interstitial cystitis patients would help to establish a minimum standard of care. A suggested treatment algorithm is provided.
PURPOSE: To examine the site, severity, and duration, of symptoms in patients with interstitial cystitis. To examine the treatments offered. MATERIALS AND METHODS: Postal questionnaire administered to members of the Interstitial Cystitis Support Group, based in the United Kingdom. RESULTS: 736 of 1148 (64%) questionnaires were returned. 696 (94.6%) patients were women. 471 patients (64%) described daily pain when symptoms were at their worst, and 273 (37%) described daily pain at the time of survey. Most patients reported frequency, urgency and nocturia. A wide range of treatments had been offered, but drugs of proven efficacy were offered to less than a third of patients: cimetidine (36%); antihistamines (5%); pentosan polysulphate (12%); DMSO (33%); and anticonvulsants (2%). 495 patients (67%) reported "considerable impact" or more on their lifestyle and 346 (46%) reported moderate depression or worse. 364 (49%) reported at least considerable difficulties with sexual intercourse. CONCLUSIONS: This survey supports the work of others about the nature of symptoms and their impact upon quality of life. The data highlight the continuing difficulty in making a prompt diagnosis. We recommend that a European survey or registry of interstitial cystitispatients would help to establish a minimum standard of care. A suggested treatment algorithm is provided.
Authors: John W Warren; Walter A Meyer; Patty Greenberg; Linda Horne; Christina Diggs; J Kathleen Tracy Journal: Urology Date: 2006-06 Impact factor: 2.649
Authors: J Quentin Clemens; Daniel J Clauw; Karl Kreder; John N Krieger; John W Kusek; H Henry Lai; Larissa Rodriguez; David A Williams; Xiaoling Hou; Alisa Stephens; J Richard Landis Journal: J Urol Date: 2014-11-13 Impact factor: 7.450
Authors: Philip M Hanno; David Allen Burks; J Quentin Clemens; Roger R Dmochowski; Deborah Erickson; Mary Pat Fitzgerald; John B Forrest; Barbara Gordon; Mikel Gray; Robert Dale Mayer; Diane Newman; Leroy Nyberg; Christopher K Payne; Ursula Wesselmann; Martha M Faraday Journal: J Urol Date: 2011-04-16 Impact factor: 7.600